ReviewFrontiers in oncology2025
Advances in the study of FOXQ1: biological functions and mechanisms.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic degradation of repressive transcription factors gates gene expression and cell fate specification.bioRxiv : the preprint server for biology · 2026Article
- Multi-Target Photoprotection by Taxifolin Against UVB-Induced Keratinocyte Injury Through UVB Filtration, ROS Scavenging and Transcriptomic-Proteomic Reprogramming.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forkhead box Q1 (FOXQ1) is a member of the Forkhead box gene family and an important transcription factor closely associated with several human diseases, especially tumorigenesis and tumor progression. This review aims to explore advances in the study of the biological functions of FOXQ1 in several tumors, such as colorectal cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, lung cancer, hepatocellular cancer, pancreatic cancer, gastric cancer, melanoma, bone-related disease, immune and inflammatory disease, regulatory factors of FOXQ1 expression, and mechanism of tissue-specific function. FOXQ1 influences the pathological progression of these diseases through different targets genes and signaling pathways, which we also review in detail. In conclusion, more and more FOXQ1 applications and different pathologic mechanisms are bound to be reported in future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.